Drug pricing and control of health expenditures: a comparison between a proportional decision rule and a cost-per-QALY rule

摘要

Background and aimsIn Germany, the Institute for Quality and Efficiency in Health Care (IQWiG) makes recommendations for reimbursement prices of drugs on the basis of a proportional relationship between costs and health benefits. This paper analyzed the potential of IQWiG's decision rule to control health expenditures and used a cost-per-quality-adjusted life year (QALY) rule as a comparison.